02 October 2023
02 October 2023
The scandal resulted in the suspension of Atlantic Pharma's import license and potential legal action against Maiden Pharma.
The FDA has set 31 March 2024 as the PDUFA action date for reviewing odronextamab as third-line therapy for FL and DLBCL.
Thymmune Therapeutics is undertaking the eponymous Thymus Rejuvenation project, which aims to restore damaged or non-functional thymus tissue.
The NDA submission for KarXT includes long-term safety and efficacy data from three placebo-controlled trials.
ModeX will receive a $59m upfront payment for the research and development of multi-specific antibodies against viral infections as part of Project NextGen.
At the industry crossroads of healthcare and pharmaceuticals at the Life Sciences Baltics 2023 conference, all signs pointed towards an AI-based future.
Manufacturers of the selected drugs must sign an agreement with the Centers for Medicare and Medicaid Services to participate in drug price negotiations by 1 October 2023.
Obesity can cause and exacerbate other conditions such as heart disease, which is responsible for 16% of deaths worldwide according to the World Health Organization (WHO).
The Excellence Awards celebrate the greatest achievements and innovations in the industry, and the people and companies that are driving change.
With only a few approved drugs currently available to treat DN by means other than regulation of blood pressure, innovator products that can treat by targeting other factors such as treatment of dyslipidemia, hypertension, or angiotensin inhibition, among others, is a key area of R&D in the DN space and is likely to pave the way for novel therapies in the near future. However, the treatment landscape is expected to remain unchanged due to limited availability of products in the late-stage pipeline currently.
Give your business an edge with our leading industry insights.
